Cellebrite DI annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Cellebrite DI R&D Spending Growth & History (CLBT)
Cellebrite DI's r&d spending was $113.9M for fiscal 2025.
View full Cellebrite DI company overviewCellebrite DI annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $113.9M | $15.5M | +15.71% |
| 2024 | 2024-12-31 | $98.4M | $14.0M | +16.62% |
| 2023 | 2023-12-31 | $84.4M | $3.8M | +4.67% |
| 2022 | 2022-12-31 | $80.6M | $15.1M | +23.01% |
| 2021 | 2021-12-31 | $65.5M | $11.2M | +20.53% |
| 2020 | 2020-12-31 | $54.4M | $7.8M | +16.76% |
| 2019 | 2019-12-31 | $46.6M | — | — |
Cellebrite DI quarterly r&d spending
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $36.0M | $7.3M | +25.69% |
| Q1 2026 | 2026-03-31 | $35.9M | $8.6M | +31.51% |
| Q4 2025 | 2025-12-31 | $29.9M | — | — |
| Q3 2025 | 2025-09-30 | $28.1M | — | — |
| Q2 2025 | 2025-06-30 | $28.6M | — | — |
| Q1 2025 | 2025-03-31 | $27.3M | — | — |
Cellebrite DI r&d spending trends
Over the last five fiscal years, Cellebrite DI's r&d spending increased from $54.4M to $113.9M, a change of $59.5M. The latest reported quarter, Q2 2026, shows $36.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cellebrite DI source filings ↗